AfDB provides $15m to Biovac for new multi-vaccine production facility

Development finance institution the African Development Bank (AfDB) Group has finalised a $15-million loan to biopharmaceutical company Biologicals and Vaccines Institute of South Africa (Biovac) to support a new multi-vaccine manufacturing facility in Cape Town that will significantly expand Africa’s domestic capacity to produce vaccines. The expansion programme will increase Biovac’s total yearly manufacturing capacity to 500-million doses. Biovac’s new facility is expected to be completed by 2028 and will initially produce vaccines for cholera (oral) and subsequently for polio (IPV), pneumonia (PCV) and meningitis (MenX).

Raccontata daiol.co.zaengineeringnews.co.zaafrica.businessinsider.com